Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure

Am J Cardiol. 2016 Dec 15;118(12):1868-1874. doi: 10.1016/j.amjcard.2016.08.078. Epub 2016 Sep 15.

Abstract

Potassium levels are often abnormal in patients with heart failure (HF) and have a detrimental effect on clinical outcome. We evaluated potassium levels in a real-world cohort of patients with HF and its effect on mortality. All patients with a diagnosis of HF at a health maintenance organization were evaluated and followed for cardiac-related hospitalizations and death. The cohort consisted of 6,073 patients with HF. Mean potassium levels were 4.57 ± 0.53 mmol/L. Most patients (68%) had potassium levels in the normal range (4.0 to 5.0 mmol/L). High-normal potassium levels (5.0 to 5.5) were present in 17% of the patients, low potassium levels (<4.0) in 11%, and hyperkalemia (K ≥5.5) in 4%. Mean follow-up was 576 days. The overall mortality rate during this period was 14%. Survival rate by Kaplan-Meier analysis demonstrated that hypokalemia (K ≤3.5) was associated with the lowest survival rate. Survival was highest in patients with high-normal potassium levels. Cox regression analysis after adjustment for significant predictors including co-morbidities and standard HF drug therapies demonstrated that high-normal potassium levels were independently associated with reduced mortality compared with normal reference levels (hazard ratio 0.78, 95 confidence interval [CI] 0.64 to 0.95, p = 0.01). Subgroup analysis showed improved outcome with high-normal potassium levels in patients with reduced renal function, spironolactone, and loop diuretic therapy. In conclusion, potassium levels in the high-normal range appear to be safe and are associated with an improved outcome in patients with HF.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Chronic Disease
  • Cohort Studies
  • Diuretics / therapeutic use
  • Female
  • Heart Failure / blood*
  • Heart Failure / mortality
  • Humans
  • Hyperkalemia / blood
  • Hyperkalemia / epidemiology
  • Kaplan-Meier Estimate
  • Male
  • Mortality
  • Potassium / blood*
  • Prognosis
  • Proportional Hazards Models
  • Protective Factors
  • Renal Insufficiency, Chronic / epidemiology
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use
  • Spironolactone / therapeutic use
  • Survival Rate*

Substances

  • Diuretics
  • Sodium Potassium Chloride Symporter Inhibitors
  • Spironolactone
  • Potassium